*Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).

• About Ventavis

•      Indications

•      Clinical Trials

•           Clinical Improvement

•           Improved Exercise
            Capacity

•           Functional Class
            Improvement

•           Improved
            Hemodynamics

•      Safety Profile

•      Dosage & Administration

•      FAQs

•      Ventavis Support

• About the I-neb AAD
  System

• Services for Your Patients

• Resources

• Prescribing Information

• For Patients and
  Caregivers

Efficacy

Ventavis^® (iloprost) Inhalation Solution is a synthetic analogue of prostacyclin PGI₂.¹ It dilates system and pulmonary arterial vascular beds. It also affects platelet aggregation, although the relevance of this effect to the treatment of pulmonary arterial hypertension* is unknown.¹

In clinical studies, Ventavis has been shown to help with the following^1,2:

• Significant improvement in a combined endpoint of patient improvement—improvement in functional class, 10% or greater increase in individual walk distance, and lack of clinical deterioration or death (p=0.0033)^{1,2 †}
• Significant improvement in exercise capacity (p<0.01)^{1,2 †}
• Significant improvement in NYHA functional class (p=0.03)^1,2

Read more about How Ventavis Helps Patients:

• Clinical Improvement
• Improved Exercise Capacity
• Functional Class Improvement
• Improved Hemodynamics
• Safety Profile

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information